A federal court finds that W.L. Gore was not a co-inventor of vascular grafts patented by C.R. Bard, affirming a lower court's $371 million decision in favor of Bard. Analysts weigh in and Wall Street gives Bard some love.
Updated Feb. 10, 2012, at 1:30 p.m. with share values and analysts' reactions.
A U.S. federal judge this week upheld C.R. Bard's (NYSE:BCR) win against W.L. Gore & Associates over vascular graft patents.
The court affirmed Bard's $371 million win from a 2007 decision when an Arizona jury found that Gore willfully infringed on patents for vascular tubing.
"This has been a long and arduous journey for the parties in this litigation, but this should be the final curtain of the saga," Circuit Court Judge Arthur Gajarsa of the U.S. Court of Appeals for the Federal Circuit wrote in the decision.
The news gave Bard a bump on The Street where shares were trading 2% higher at $94.36 around 1:30 p.m. today.
"Though not unexpected, this is a positive milestone for BCR," Leerink Swann analyst Rick Wise wrote in a letter to shareholders. "Our understanding is that although Gore still has several possible levels of appeals, from a practical manner, the court's ruling today will likely be very much what the final ruling will look like."
Wise predicted an earnings upside of around $1.40 to $1.50 per share as a result of the ruling. With total damages and an ongoing royalty stream considered together, Bard stands to rake in about $783 million.
The decision was split 2 to 1 and Judge Gajarsa was rather candidly dismissive of the dissenting opinion:
A new line of spinal implants from Medtronic makes its debut on the global stage.
Ablative Solutions begins testing its infusion ablation catheter as a potential treatment for...
AnthroTronix says it won FDA clearance for an app designed to help clinicians measure reaction time...
A Chinese venture capital investor takes a $5.7 million stake in incision-closure device maker...
Medtronic has initiated an IDE clinical trial for its latest insulin-pump system as part of its quest...